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Introduction
Resistance is the major factor limiting endocrine therapy. This
short communication defines the different types of resistance,
the mechanisms by which resistance may occur and how
they may be identified.
Types
Endocrine resistance may be subdivided into the following
types: primary or de novo, and secondary or acquired (occur-
ring after an initial response to treatment). The term ‘acquired’
infers that, under the pressures of treatment, inductive
molecular changes or clonal selection occurs, resulting in a
resistant cellular phenotype with an independent growth
advantage. Adaptive changes in key molecules of signalling
pathways have been observed with endocrine treatment,
such as loss of oestrogen receptors (ERs) and over-expres-
sion of c-erbB2 at relapse on tamoxifen [1]. Under these
circumstances, the underlying mechanisms of resistance might
be expected to be common to primary and secondary types.
Endocrine resistance is most often thought of in clinical terms,
but resistance may also occur at pathological, proliferative and
molecular levels. Although these parameters are positively
correlated, they are not equivalent, and disconnects between
them occur relatively frequently. For example, cell cycle
response and clinical response to tamoxifen and letrozole in
the P024 trial were discordant in over one-third of cases
despite there being a highly significant correlation between
the two types of response (P = 0.00037) [2]. Similarly, the
degree of proliferative response was not significantly different
in cases responding or not responding to endocrine treatment
in the IMPACT (Immediate Preoperative ‘Arimidex’ [anastro-
zole], Tamoxifen, or Arimidex Combined with Tamoxifen) trial
[3]. Furthermore, as illustrated below, clinically resistant
tumours frequently exhibit molecular responses.
Mechanisms of resistance
Theoretically, there are multiple mechanisms whereby breast
cancers appear unresponsive to endocrine therapy. These
include  inherent tumour insensitivity to hormone therapy,
activation of hormone signalling pathways by nonendocrine
pathways, ineffective or compromised therapy, and domination
of cell survival [4]. To determine whether these mechanisms
are apparent in primary breast cancers, the neoadjuvant
setting in which treatment is given with tumour still within the
breast has been particularly informative. Because of relatively
easy access to tumour, biopsies may be taken sequentially
before and during treatment and analyzed to monitor the
effects of treatment on molecular processes. Some of these
studies are worthy of more detailed consideration using ER
and the expression of oestrogen-regulated genes, including
KIAA0101, SERPINA3, IRS1, TFF3 and TFF1 as markers of
(anti)oestrogenic responses, and Ki67 and expression of cell
cycle/DNA synthesis genes such as CDC, CKS2, Cyclin B1,
TYMS and PCNA as markers of proliferation [5-7].
Inherent resistance
Hormone stimulation of tumour growth is generally associated
with oestrogen, whose action is mediated primarily through
the ER. It follows therefore that in ER-negative tumours
oestrogen is disconnected from growth (which is driven by
other growth factors). Therapies directed either at oestrogen
or ER are therefore unlikely to be successful in ER-negative
breast cancer. This is supported by a large volume of
literature, and we have reported that in the neoadjuvant setting
ER-negative tumours rarely respond to a variety of endocrine
therapies [8]. Additionally, as shown in Figure 1, an ER-
negative tumour treated electively with neoadjuvant letrozole
did not exhibit a major change in expression of oestrogen-
regulated and proliferation-related genes, illustrating molecular
resistance to treatment. The clinical relevance of these
observations is that patients with ER-negative tumours should
not be regarded as candidates for endocrine treatment.
However, many endocrine-resistant tumours have ER-positive
phenotypes, and the challenge is to discriminate between
ER-positive responsive and ER-positive resistant tumours,
and to clarify the underlying cause of resistance in the latter.
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It is possible to envisage an aberrant receptor that may bind
oestrogen or ER antibodies but not transduce a signal (RNAs
encoding variant and mutant ER have been reported in breast
cancer [9]). In this case, tumours would be inherently
insensitive to hormone stimulation and refractory to endocrine
deprivation therapy despite having ER-positive status.
Another scenario is that ER is functional and driving
oestrogen-dependent processes, but that growth is not one of
them, this being stimulated by other independent pathways. If
this were the case, then oestrogen-deprivation therapies
would reduce expression of classically oestrogen-regulated
genes but not those associated with cellular proliferation. This
phenotype was observed in two out of 15 ER-positive tumours
treated with neoadjuvant letrozole (Figure 1).
Activation of hormone signaling pathways by
nonendocrine pathways
In model systems, activation of other messenger systems may
influence ER signalling such that it may occur in the presence
of low oestrogen levels (hypersensitivity) or even in the
absence of hormone. Thus, even in the absence of oestrogen,
the HER (human epidermal growth factor receptor) signalling
can result in ER phosphorylation (a critical step in ER
activation) [10]. It is therefore interesting that endocrine
therapy often fails to reduce proliferation in ER-positive breast
cancers over-expressing c-erbB2 [11-13].
Ineffective or compromised therapy
Failure to respond to endocrine therapy may not necessarily
be caused by inherent tumour resistance but because the
treatment itself is inefficient or compromised. There could be
several reasons for this, including a lack of drug potency,
poor pharmocokinetics/pharmacogenetics [14] and compen-
satory endocrine loops (for example, the use of aromatase
inhibitors in premenopausal women).
Inherent resistance, ligand-independent ER signalling and
inefficient therapy could all be associated with a molecular
phenotype in which the expression of oestrogen-regulated
and proliferation-associated genes do not change markedly
with treatment. This phenotype can be seen in Figure 1, in
which four out of 15 tumours exhibit a phenotype of
molecular resistance. It should be noted that lack of change
with treatment may result from high expression not being
reduced with therapy or a low basal level of expression being
maintained, or a hybrid split according to oestrogen regula-
tion and proliferation genes. By possessing knowledge not
only of changes with treatment but also of the pretreatment
and post-treatment levels of expression, it is possible to
determine the specific type of resistance (see below).
Hypersensitivity and cell survival
However, the most common phenotype in letrozole-resistant
tumours is for both oestrogen-regulated and proliferation-
associated genes to decrease with treatment. This
observation suggests that there are other mechanisms of
resistance. These include hypersensitivity, in which tumours
continue to grow in low oestrogen environments. The
scenario would be that, despite therapy producing an overall
reduction in proliferation, residual cell cycle progression plus
effective cell survival is sufficient to maintain tumour growth.
It is clear that multiple pathways/processes may confer endo-
crine resistance. It therefore follows that their identification
will be equally diverse.
Identification of resistance
Table 1 lists some resistance mechanisms and measurements
that might help to identify them. Measurement of ER status
should be routine because patients with ER-negative tumours
rarely respond to endocrine therapy. Additionally, expression
profiles of oestrogen-regulated genes, growth factors and
their receptors can provide some indication of ER functionality
and the involvement of other growth factor pathways.
The status of ER signalling and its output may be assessed
by measuring the degree/type of ER phosphorylation and
levels of ER co-activators/co-repressors.
The efficiency of treatment may be monitored by measuring
oestrogen levels (in the case of aromatase inhibitors), down-
stream signalling of ER (in the case of selective ER modula-
tors and selective ER downregulators) and genetic poly-
Figure 1
Changes in expression of oestrogen-regulated and proliferation-
associated genes after 14 days of adjuvant treatment with letrozole.
Green represents downregulation and red upregulation (these will
show as relatively paler blocks if you are viewing this figure in black
and white). Intensity of colour/shade represents degree of change. The
single column to the left of the figure represents changes in an ER-
negative case; the panels relate to 15 different clinically resistant ER-
positive tumours: the left-hand panel illustrates a molecular resistant
phenotype; the middle panel shows cases exhibiting decreases in the
expression of oestrogen-regulated genes but not in cell cycle genes;
and the right-hand panel shows molecular sensitivity in both
oestrogen-regulated and cell cycle associated gene expression. ER,
oestrogen receptor.Page 3 of 3
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morphisms (where there is evidence that pharmacogenetics
influence drug levels or metabolism).
Based on the above considerations, it should be apparent that
no single marker will identify resistance or its mechanism -
multiple measurements and readouts will be necessary.
Finally, it should be noted that single static measurements of
biomarkers either before or during treatment are unlikely to be
definitive, and (especially to determine efficiency of treatment)
dynamic sequential assessments of tumour molecular biology
or histopathology will be required. Tissue acquisition will be a
logistical challenge if these analyses are to be undertaken on a
routine basis.
Past, present and future
The status of endocrine resistance can be put into perspective
by assessing where it has come from, where it is now and
where it is going. My personal view is that we have come from
a past of having no understanding of the mechanisms of
resistance and no rational method of identifying resistance.
We now have a basic understanding of resistance mecha-
nisms and their diversity, and we currently use ERs to help
identify resistance. However, we can look forward to a future
in which we will perform molecular phenotyping of resistant
tumours on an individual basis and devise novel rational
circumventing treatments using that knowledge.
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Table 1
Identification of resistance
Mechanism Phenotype Assessment
Inherent resistance  ER negativity ER measurement
Defective ER ER read-outs
Alternative growth signalling GF/receptor assays
ER modified ER phosphorylation Phosphorylation status
ER co-activators ER read-outs
ER co-repressors
Ineffective treatment  Inherent lack of potency Target read-outs
Compensatory mechanisms Target read-outs
Poor pharmacokinetics Pharmacogenetics
ER, oestrogen receptor; GF, growth factor.